⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VRDN News
Viridian Therapeutics, Inc. Common Stock
4 Sizzling Biotech and Healthcare Companies Reporting Strategic Milestones
globenewswire.com
UPC
NTHI
DCOY
VRDN
Form 8-K
sec.gov
VRDN
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
businesswire.com
VRDN
Form 8-K
sec.gov
VRDN
Form 8-K
sec.gov
VRDN
Form 8-K
sec.gov
VRDN
Form 8-K
sec.gov
VRDN
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
businesswire.com
VRDN
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
businesswire.com
VRDN
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
businesswire.com
VRDN